Key Dates

Related Announcements

• September 6, 2023 - Notice of Special Interest (NOSI): Quantum Sensing in Biomedical Applications (SBIR/STTR). See Notice NOT-EY-23-009.

Issued by

National Heart, Lung, and Blood Institute (NHLBI)

Purpose

The purpose of this Notice is to inform potential applicants that the NHLBI is participating, effective immediately, in NOT-EY-23-009 "Notice of Special Interest (NOSI): Quantum Sensing in Biomedical Applications (SBIR/STTR)."
 

The National Heart, Lung, and Blood Institute (NHLBI) provides global leadership for a research, training, and education programs to promote the prevention and treatment of heart, lung, blood and sleep disorders or conditions.

Research Objectives
Under this SBIR/STTR NOSI, NHLBI is interested in supporting applications that utilize advances in quantum technologies to support commercializable product development that aligns with the NHLBI mission. Applicants are strongly encouraged to contact Scientific/Research staff noted below NOSI about proposed activities prior to submission. 

Research Examples
Topics of interest include, but are not limited to:

• Next-generation quantum technology imaging systems to improve detection and diagnosis of diseases relevant to NHLBI
• Portable quantum sensors for ultrasensitive in vivo non-invasive measurements of early biomarkers of HLBS diseases or conditions (e.g., fetal magnetocardiography)
• Quantum sensor technologies to better understand biological mechanisms of HLBS diseases, track disease progression and response to treatment (e.g., SCD vaso-occlusive crises, lung fibrosis)
• Innovative quantum sensing approaches to modalities including microscopy, spectroscopy, NMR, such as hyperpolarized MRI, quantum OCT and photon-counting CT
• Quantum technologies for developing lab-on-a-chip systems and microfluidic approaches for point-of-care diagnostics and screening new therapeutics for HLBS conditions
• Quantum sensors for drug efficacy assessment; quantum sensing NMR to study drug - target interactions at the atomic level
• Novel algorithms and quantum-classical computational solutions for enabling use of the quantum devices and technologies, for development of biomanufacturing tools, and for in silico discovery of personalized treatments. 

Inquiries

Please direct all inquiries to:

Scientific/Research Contact(s)
Julia Berzhanskaya, Ph.D. 
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-443-3707
Email: julia.berzhanskaya@nih.gov

John Haller, Ph.D.
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0513 
Email: julia.berzhanskaya@nih.gov

Financial/Grants Management Contact(s)
Julie Delgado
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0833
Email: julie.delgado@nih.gov